BRPI0817200A2 - composições oftálmicas sólida e uso de compostos para fabricação de medicamento - Google Patents

composições oftálmicas sólida e uso de compostos para fabricação de medicamento

Info

Publication number
BRPI0817200A2
BRPI0817200A2 BRPI0817200A BRPI0817200A BRPI0817200A2 BR PI0817200 A2 BRPI0817200 A2 BR PI0817200A2 BR PI0817200 A BRPI0817200 A BR PI0817200A BR PI0817200 A BRPI0817200 A BR PI0817200A BR PI0817200 A2 BRPI0817200 A2 BR PI0817200A2
Authority
BR
Brazil
Prior art keywords
ophthalmic compositions
pharmaceutical manufacturing
manufacturing compounds
solid ophthalmic
solid
Prior art date
Application number
BRPI0817200A
Other languages
English (en)
Inventor
L Edelman Jeffrey
M Harrison Kelly
T Spada Lon
M Hughes Patrick
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0817200A2 publication Critical patent/BRPI0817200A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0817200A 2007-09-21 2008-09-18 composições oftálmicas sólida e uso de compostos para fabricação de medicamento BRPI0817200A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/859,627 US20090082321A1 (en) 2007-09-21 2007-09-21 Steroid containing drug delivery systems
PCT/US2008/076837 WO2009039262A2 (en) 2007-09-21 2008-09-18 Steroid containing ophthalmic drug delivery systems

Publications (1)

Publication Number Publication Date
BRPI0817200A2 true BRPI0817200A2 (pt) 2017-01-31

Family

ID=40409724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817200A BRPI0817200A2 (pt) 2007-09-21 2008-09-18 composições oftálmicas sólida e uso de compostos para fabricação de medicamento

Country Status (7)

Country Link
US (3) US20090082321A1 (pt)
EP (1) EP2200581A2 (pt)
JP (2) JP2010540447A (pt)
AU (1) AU2008302309B2 (pt)
BR (1) BRPI0817200A2 (pt)
CA (1) CA2700072C (pt)
WO (1) WO2009039262A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US20100098772A1 (en) * 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
KR101763440B1 (ko) 2009-12-03 2017-08-14 옵코 헬스, 인크. 과황산화 이당 제제
EP2512389B1 (en) 2009-12-16 2015-09-02 Allergan, Inc. Intracameral devices for sustained delivery
US8647659B2 (en) * 2010-01-22 2014-02-11 Allergan, Inc. Intracameral sustained release therapeutic agent implants
CA2796307A1 (en) * 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EA028375B1 (ru) * 2010-09-03 2017-11-30 Сантен Сас Композиция в виде эмульсии типа "вода-в-масле" для интраокулярного введения
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
EP2627292B1 (en) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Device for ocular access
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9241829B2 (en) 2011-12-20 2016-01-26 Abbott Medical Optics Inc. Implantable intraocular drug delivery apparatus, system and method
CN107880091B (zh) 2012-05-08 2020-12-18 尼科斯眼药公司 疏水性治疗剂的制剂、其制备方法及应用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
KR102467714B1 (ko) 2012-11-08 2022-11-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CA2907765C (en) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
EP2986635B1 (en) 2013-04-18 2018-10-03 Fondazione Telethon Effective delivery of large genes by dual aav vectors
AU2014259694B2 (en) 2013-05-03 2018-11-08 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
SG10201800978UA (en) 2013-10-31 2018-03-28 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
DK3068403T3 (da) * 2013-11-15 2020-09-07 Allergan Inc Fremgangsmåder til behandling af øjentilstande med et implantat med langvarig lægemiddelfrigivelse
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
TW201720427A (zh) 2015-10-27 2017-06-16 優普順藥物股份有限公司 局部麻醉劑之持續釋放調配物
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US11096993B2 (en) 2016-12-08 2021-08-24 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US11123411B2 (en) 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
JP7357367B2 (ja) * 2017-07-11 2023-10-06 サステインドナノシステムズエルエルシー 超圧縮ポリマー剤形の放射線殺菌
WO2023201315A2 (en) * 2022-04-14 2023-10-19 TearClear Corp. Ophthalmic agent in preservative removal device

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE442820B (sv) * 1984-06-08 1986-02-03 Pharmacia Ab Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0224987B1 (en) * 1985-11-29 1992-04-15 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
JP3404557B2 (ja) * 1993-09-30 2003-05-12 グンゼ株式会社 架橋ヒアルロン酸及びこれらの複合材料
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
JP2000119196A (ja) * 1998-10-07 2000-04-25 Menicon Co Ltd 眼科用薬剤徐放材及びその製造方法
CN1320880C (zh) * 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
GB0328630D0 (en) * 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
CA2573668A1 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
WO2007047607A2 (en) * 2005-10-18 2007-04-26 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Also Published As

Publication number Publication date
CA2700072C (en) 2016-08-09
WO2009039262A2 (en) 2009-03-26
US20090082321A1 (en) 2009-03-26
US20150265633A1 (en) 2015-09-24
JP2010540447A (ja) 2010-12-24
US20110077229A1 (en) 2011-03-31
WO2009039262A3 (en) 2009-05-07
EP2200581A2 (en) 2010-06-30
AU2008302309A1 (en) 2009-03-26
AU2008302309B2 (en) 2014-09-25
CA2700072A1 (en) 2009-03-26
JP2015091858A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
BRPI0820665A2 (pt) compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
BRPI0813105A2 (pt) Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
CU23871B1 (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0807487A2 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
PT2124638T (pt) Composição de aperfeiçoamento de desempenho e utilização da mesma
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL